Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Read-Gene Spółka AkcyjnafiledCriticalRead-Gene Spółka Akcyjna
Priority to PL439313ApriorityCriticalpatent/PL244361B1/en
Publication of PL439313A1publicationCriticalpatent/PL439313A1/en
Publication of PL244361B1publicationCriticalpatent/PL244361B1/en
G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
G01N33/84—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving inorganic compounds or pH
Abstract
Przedmiotem zgłoszenia jest sposób określenia ryzyka raka, charakteryzujący się tym, że obejmuje ilościową ocenę stężenia arsenu w próbce biologicznej osoby badanej, przy czym stężenie arsenu wskazuje na znacząco obniżone ryzyko: rozwoju raka w przypadku występowania niskiej wartości stężenia arsenu we krwi, zwłaszcza poniżej 0,59 µg/l.The subject of the application is a method of determining the risk of cancer, characterized by the fact that it includes a quantitative assessment of the arsenic concentration in a biological sample of the test subject, the arsenic concentration indicating a significantly reduced risk of: developing cancer in the presence of a low arsenic concentration in the blood, especially below 0, 59 µg / l.
PL439313A2018-05-172018-05-17Method for determining the risk of cancers in women, depending on concentration of arsenic in the blood
PL244361B1
(en)
Human monoclonal antilipoarabinomannan (anti-lam) antibody, kit for detecting at least one lam epitope, method for diagnosing an active tuberculosis infection in an individual, method for treating a tuberculosis infection in an individual, human anti-lam monoclonal antibody and lam preconcentration method from a biological sample
Method for determining the risk of cancers in women, depending on concentration of arsenic in the blood of women who are carriers of the most common BRCA1 and BRCA2 gene mutations
Method for determining the risk of cancers in women, depending on concentration of zinc in the blood of women who are carriers of the most common BRCA1 and BRCA2 gene mutations